LifeCell Corporation engages in the development and marketing of human-derived tissue-based products for use in reconstructive, orthopedic, and urogynecologic surgical procedures to repair soft tissue defects. It produces a regenerative human tissue matrix, a three-dimensional structure that contains vascular channels, proteins, and growth factor binding sites, that provide a template for the regeneration of normal human tissue. The company’s products include AlloDerm, which is used for plastic reconstructive, general surgical, burn, and periodontal procedures; Cymetra, a particulate form of AlloDerm suitable for injection; GraftJacket and GraftJacket Xpress for orthopedic applications and lower extremity wounds; AlloCraftDBM for bone grafting procedures; and Repliform for urogynecologic surgical procedures. The company sells its products primarily to plastic surgeons, general surgeons, burn surgeons, as well as ear, nose, and throat surgeons. It operates primarily in the United States. The company sells its products through sales and marketing agents, and distributors. It has strategic sales and marketing partnerships with Boston Scientific for Repliform; Wright Medical Group, Inc. for GraftJacket and GraftJacket Xpress; Stryker Corporation for AlloCraftDBM; and BioHorizons for periodontal applications of AlloDerm.

        Want volatility? This is the stock for you! I first owned this stock five years ago and got in at $6 and change. It has preformed great for my club and myself over those years. It still continues to grow at a substantial 40-50% growth. It will slow, but I think not for the next three to five years. I have estimated the growth rates for LIFC at 25%. The chart is all over the place but it is still a fairly young un’. EPS is currently .53 with a PE of 44.0. Seems high but as of this quarter it has met those growth rates.